CINAkit HCMV ppUL83 (pp65) RAPID ANTIGENEMIA Complete kit |
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||
|
|
||||||||||||||||||||||||
|
The optimized blend of clones (CINApool) is specific for the internal matrix structural phosphoprotein 65-68 kDa ppUL83 (pp65), which appears in the nuclei of infected cells within one hour post infection, and represents uptake from the virus innoculum. This blend labels two different epitopes expressed in the nuclei of infected peripheral blood polymorphonuclear leukocytes and monocytes, following blood born dissemination (it can also be used on cellular cerebro-spinal fluid). The HCMV isolation from leukocytes of peripheral blood and/or ppUL83 Antigenemia is evidence of an active systemic infection. The ppUL83 Antigenemia appears earlier and is positive for a longer period than viremia as demonstrated by co-culture. It is also a clearly shorter procedure (results within 2 hours). It enables the diagnosis and follow up of HCMV disseminated infections in graft recipients and AIDS patients notably. Immunofluorescence is the only recommended detection method, although others can be used. However different studies show that any technique used to block endogenous enzymatic activity (peroxidase or alkaline phosphatase), also destroys a significant level of the ppUL83 antigen. No cross reactivity with other Herpesviridae.
This blend has multiple advantages: 1/ This antibody pool labels different epitopes expressed in the nuclei of infected peripheral blood polymorphonuclear leukocytes and monocytes, and thus ensures avoiding false negatives that can be caused by a mutation of one of the epitopes recognized, since a double mutation in two specific parts of the antigen is at very low risk. 2/ Improved reading even if the sample does not reach the laboratory under optimum conditions. 3/ This anti ppUL83 pool is also of interest since it stains a higher number of cells in positive samples when compared to a monoclonal alone. 4/ To date, no lack of sensitivity has been reported with this kit regardless of the CMV strain studied. Important: secondary antibodies other than the one provided in the kit can give cytoplasmic background. |
||||||||||||||||||||||||
For in vitro diagnostic use, CE marking in Europe - Please inquire. USA: kit 19-0028 is registered by FDA for in vitro diagnostic use Code 19-002 not available in the USA. |
||||||||||||||||||||||||